Revisão Acesso aberto Revisado por pares

HPV Associated Head and Neck Cancer

2016; Multidisciplinary Digital Publishing Institute; Volume: 8; Issue: 8 Linguagem: Inglês

10.3390/cancers8080075

ISSN

2072-6694

Autores

Tara Spence, Jeff Bruce, Kenneth W. Yip, Fei‐Fei Liu,

Tópico(s)

Viral-associated cancers and disorders

Resumo

Head and neck cancers (HNCs) are a highly heterogeneous group of tumours that are associated with diverse clinical outcomes. Recent evidence has demonstrated that human papillomavirus (HPV) is involved in up to 25% of HNCs; particularly in the oropharyngeal carcinoma (OPC) subtype where it can account for up to 60% of such cases. HPVs are double-stranded DNA viruses that infect epithelial cells; numerous HPV subtypes, including 16, 18, 31, 33, and 35, drive epithelial cell transformation and tumourigenesis. HPV positive (HPV+) HNC represents a distinct molecular and clinical entity from HPV negative (HPV−) disease; the biological basis for which remains to be fully elucidated. HPV positivity is strongly correlated with a significantly superior outcome; indicating that such tumours should have a distinct management approach. This review focuses on the recent scientific and clinical investigation of HPV+ HNC. In particular, we discuss the importance of molecular and clinical evidence for defining the role of HPV in HNC, and the clinical impact of HPV status as a biomarker for HNC.

Referência(s)